Evidence map›Paper›PMID 39161833›Full record

ArticleHeliyon2024

DOE-based process optimization for development of efficient methods for purification of recombinant hepatitis B surface antigen from

Maryam Moazami Goodarzi, Reza Jalalirad, Delaram Doroud, Hamidreza Hozouri, Mohammad Reza Aghasadeghi

Abstract read
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Maryam Moazami GoodarziDepartment of Research and Development, Production and Research Complex, Pasteur Institute of Iran, 3159915111, Karaj, Iran.
Reza JalaliradDepartment of Research and Development, Production and Research Complex, Pasteur Institute of Iran, 3159915111, Karaj, Iran.
Delaram DoroudDepartment of Research and Development, Production and Research Complex, Pasteur Institute of Iran, 3159915111, Karaj, Iran.
Hamidreza HozouriDepartment of Research and Development, Production and Research Complex, Pasteur Institute of Iran, 3159915111, Karaj, Iran.
Mohammad Reza AghasadeghiDepartment of Hepatitis and AIDS, Pasteur Institute of Iran, 1316943551, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The multimodal chromatography resins, such as Capto adhere, are considered good candidates to be utilized in downstream processing due to their high capacity and selectivity; however, their multimodal interactions lead to an intricacy in the adsorption-desorption patterns and systematic characterization of conditions for process steps is necessary. Methods: Capto adhere, a strong ion exchanger with multimodal functionality, was used in this study for the final aim of recombinant hepatitis B surface antigen (rHBsAg) purification from Results: Maximum rHBsAg binding on Capto adhere occurred in 20 mM sodium acetate, pH 4.5, and a binding capacity of about 0.75 mg/ml was achieved, which was much higher than rHBsAg binding capacity of other resins reported so far. In elution optimization investigations, it was revealed that 1 M arginine (buffered in 50 mM sodium phosphate, pH 6.5) was the most efficient eluting agent. The binding and elution optimal conditions were utilized for further purification of rHBsAg from Conclusions: These results suggest that Capto adhere under such optimized conditions can be considered as a good candidate for efficient purification of rHBsAg from

Indexed as

Capto adhereDesign of experiments (DOE)Downstream processingProcess optimizationrHBsAg purification

Identifiers

PMID39161833
PMCPMC11332888

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.